-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Shanghai, China and Gaithersburg, USA October 18, 2021/PRNewswire/ - Tianjing Bio ("Company") (NASDAQ: IMAB) is a company that is moving from the clinical stage to commercialization Biopharmaceutical companies are committed to target biological research of innovative biological drugs, antibody technology, clinical development and product commercialization in China and the United States, and provide new and effective treatment methods for the urgently needed cancer treatment fields around the world
Efeinterleukin alpha is the world’s first and only long-acting recombinant human interleukin 7 (rhIL-7) drug.
A number of clinical studies on the treatment of advanced solid tumors with single-drug and PD-1 antibody combination have been carried out in the United States, South Korea and China
Dr.
At the same time, Tianjing Biological is rapidly advancing another phase 2 clinical trial (NCT04600817) for the treatment of glioblastoma (GBM) with effl-interleukin alpha in China, aiming to complete GBM patients with lymphopenia after standard concurrent radiotherapy and chemotherapy To evaluate the efficacy and safety of efinterleukin alpha, the study has completed the first patient administration in February 2021
[1] The data can be viewed in the report published by NeoImmuneTech at the 2021 ASCO Annual Meeting, the link is as follows: http://neoimmunetech.
About Efeil Interleukin Alpha
Efeinterleukin alpha (also known as TJ107/GX-I7/NT-I7) is the world’s first and only long-acting recombinant human interleukin 7 (rhIL-7), which can increase the number of T lymphocytes and Improve T cell function to promote T lymphocyte proliferation
About Tianjing Biological
Tianjing Bio (Nasdaq: IMAB) is an innovative international biotechnology company focusing on the R&D, production and commercialization of differentiated and innovative biological drugs in the field of tumor immunity
Forward-looking statement
This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including clinical trial data regarding non-interleukin alpha, and the potential impact of clinical trial data on patients.
